Drug Profile
Prednisolone metasulfobenzoate sodium controlled-release - Alizyme
Alternative Names: ATL-2502; COLAL-PRED; TSD-0011Latest Information Update: 20 Feb 2012
Price :
$50
*
At a glance
- Originator Alizyme
- Developer Alizyme; Norgine; Prometheus Laboratories; TSD Japan
- Class Anti-inflammatories; Antiallergics; Antirheumatics; Glucocorticoids; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Suspended Ulcerative colitis
Most Recent Events
- 31 Jul 2011 Prometheus Laboratories has been acquired by Nestle
- 25 Feb 2011 Suspended - Phase-II for Ulcerative colitis in USA (PO)
- 20 Dec 2010 No development reported - Phase-I for Ulcerative colitis in Japan (PO)